| Expression of PRMT5 was significantly increased in human gastric cancer (GC) tissues compared with normal gastric mucosa. Multiple evidences suggested that PRMT5 repressed transcription of tumor suppressor IRX1 via recruitment of DNMT3A on promoter. | gastric, |
| results suggest distinct functions of the nuclear and the p44/protein arginine methyltransferase 5 complexes in the developing fetal testis and in the oncogenesis of testicular tumors. | testicular, |
| PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers | lymphoma, |
| PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. | lymphoma, |
| Study showed that PRMT5 mRNA levels were significantly higher in gastric cancer (GC) tissues and were independent of tumor depth, differentiation and lymph node metastasis. Findings indicate that PRMT5 acts as an oncogene in GC by enhancing the malignant phenotype of a cancer cell line. | gastric, |
| our results indicate that PRMT5 may act as a putative oncogene in hepatocellular carcinoma | liver, |
| PRMT5 may play a role from early oncogenesis through to the progression of oral squamous cell carcinoma , particularly in the aggressive mode of stromal invasion | oral |
| A protein methyl transferase, PRMT5, selectively blocks oncogenic ras-p21 mitogenic signal transduction. | None |
| Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. | None |